Alpha-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving immune checkpoint inhibitors with or without tyrosine kinase inhibitors or locoregional therapies.
Wei‐Fan Hsu(China Medical University), Cheng‐Yuan Peng(China Medical University), Wen‐Pang Su(China Medical University), Po‐Heng Chuang(China Medical University), Sheng‐Hung Chen(China Medical University), Hung‐Yao Chen(China Medical University), Guan‐Tarn Huang(National Taiwan University Hospital), Hung‐Wei Wang(China Medical University), Wang‐De Hsiao(China Medical University), Jen‐Wei Chou, Chia‐Sheng Chu(China Medical University), Hung‐Chun Lai(National Yang Ming Chiao Tung University), Cheng‐Kuo Chen(Asia University)
PubMed
January 1, 2021
Cited by 19
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
|Annals of Internal Medicine|2016|364
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
|The Lancet|2014|343
Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.
|Molecular and Cellular Biology|1994|284